Bimoptik Rompharm, eye drops 0.3 mg/ml 3 ml

Bimatoprost reduces intraocular pressure in humans by increasing aqueous outflow through the trabecular meshwork and increasing uveoscleral outflow. The decrease of intraocular pressure starts about 4 hours after the first injection and the maximum effect is reached after about 8-12 hours.

Indications

Reduction of elevated intraocular pressure in open-angle glaucoma and ophthalmohypertension in adults (as monotherapy or in combination with beta-adrenoblockers).

Active ingredient

Bimatoprost

Interaction

No special studies on the interaction of BIMOPTIC ROMPHARM with other medicinal products have been conducted.

Directions for use

The recommended dose is one drop in the affected eye(s) once a day in the evening.

Special Instructions

Patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation before starting treatment.

Contraindications

Hypersensitivity to the active substance or any of the excipients, age under 18 years.

Side effects

The following adverse events have been reported in clinical studies and in the post-registration period. The frequency of occurrence is given according to the following classification: very common (>1/10); common (>1/100 to <1/10); infrequent (>1/1000 to <1/100); rare (>1/10000 to <1/1000); very rare (<1/10000) and unknown frequency (cannot be estimated based on available data). Within each group, adverse effects are presented in descending order of severity.

Overdose

No cases of overdose have been reported with topical application.

Pregnancy use

Fertility

Similarities

Bimatan